P&PMed
Xuhui · Founded 2018
About P&PMed
Geyuan Zhishan is the first biomedical company to focus on the research and application of personalized cancer vaccines. Focus on a standardized system for the prediction and evaluation of new antigens to establish and personalize clinical treatment studies for tumor vaccines. Geyuan’s technology is derived from the State Key Laboratory of Medical Immunology and Medical Immunology of the Second Military Medical University. The company adheres to the "new antigen" + "personalized tumor vaccine" as a double wing, which can quickly develop targeted personalized cancer prevention and treatment vaccines based on the results of tumor gene mutations, and provide accurate medical solutions for the whole tumor cycle. The company has introduced research and development teams of interdisciplinary scientists such as computational biology, genetic testing, and cellular immunity. It has applied for a number of patents on the frontier precision medical technology such as early tumor screening and personalized tumor vaccines.
Company Facts
- Founded: 2018
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $1.4M
- Funding stage: Seed
- Last round: Angel (Dec 2018)
- Website: http://www.pnp-med.com
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/p-pmed-166635 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.